The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents

Sleep

Volumn 32, Issue 11, 2009, Pages 1425-1438

  Gruner, John A ^a   Marcy, Val R ^a   Lin, Yin Guo ^a   Bozyczko Coyne, Donna ^a   Marino, Michael J ^a   Gasior, Maciej ^a  

^a CEPHALON INC   (United States)

Author keywords

Amphetamine; Dopamine transporter; Hypersomnolence; Pharmacokinetic; Rat; Sleep wake

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; AMFEBUTAMONE; AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; NOMIFENSINE; PHENTERMINE; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; HABITUATION; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; REBOUND HYPERSOMNOLENCE; SLEEP INDUCTION; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; SOMNOLENCE; SYNAPTOSOME; WAKEFULNESS;

EID: 70649099211     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/32.11.1425     Document Type: Article

References (69)

1. Berridge CW. Neural substrates of psychostimulant-induced arousal. Neuropsychopharmacology 2006;31:2332-2340
2. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004;27:1181-1194 (Pubitemid 39331091)
3. Dzirasa K, Ribeiro S, Costa R, et al. Dopaminergic control of sleep-wake states. J Neurosci 2006;26:10577-10589
4. Trampus M, Ferri N, Adami M, Ongini E. The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. Eur J Pharmacol 1993;235:83-87 (Pubitemid 23124072)
5. Gessa GL, Porceddu ML, Collu M, et al. Sedation and sleep induced by high doses of apomorphine after blockade of D-1 receptors by SCH 23390. Eur J Pharmacol 1985;109:269-274 (Pubitemid 15141404)
6. Isaac SO, Berridge CW. Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J Pharmacol Exp Ther 2003;307:386-394 (Pubitemid 37151931)
7. Bagetta G, De Sarro G, Priolo E, Nistico G. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats. Br J Pharmacol 1988;95:860-866 (Pubitemid 18266264)
8. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 2003;87:273-289
9. Dickinson SD, Sabeti J, Larson GA, et al. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 1999;72:148-156 (Pubitemid 29013888)
10. Svensson K, Alfoldi P, Hajos M, et al. Dopamine autoreceptor antagonists: effects on sleep-wake activity in the rat. Pharmacol Biochem Behav 1987;26:123-129 (Pubitemid 18005614)
11. Wauquier A. Drug effects on sleep-wakefulness patterns in dogs. Neuropsychobiology 1983;10:60-64 (Pubitemid 14245449)
12. Lelkes Z, Obal F, Jr., Benedek G, Rubicsek G, Alfoldi P, Obal F. Effects of acute and chronic treatment with an atypical antidepressant drug, nomifensine, on the sleep-wake activity in rats. Naunyn Schmiedebergs Arch Pharmacol 1987;335:149-153 (Pubitemid 17007992)
13. Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998;1:49-61.
14. Kanbayashi T, Honda K, Kodama T, Mignot E, Nishino S. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Neuroscience 2000;99:651-659 (Pubitemid 30682417)
15. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-1794
16. Sulzer D, Maidment NT, Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 1993;60:527-535 (Pubitemid 23030947)
17. Jones SR, Joseph JD, Barak LS, Caron MG, Wightman RM. Dopamine neuronal transport kinetics and effects of amphetamine. J Neurochem 1999;73:2406-2414
18. Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A. Amphetamine- induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem 2003;278:12070-12077 (Pubitemid 36800184)
19. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997;283:757-769
20. Hou YP, Lin JS. Effects of modafinil and amphetamine on sleep-wake cycle after sleep deprivation in cats. Zhongguo Yao Li Xue Bao 1999;20:813-818 (Pubitemid 29459747)
21. Lin JS, Gervasoni D, Hou Y, et al. Effects of amphetamine and modafinil on the sleep/wake cycle during experimental hypersomnia induced by sleep deprivation in the cat. J Sleep Res 2000;9:89-96.
22. Touret M, Sallanon-Moulin M, Jouvet M. Awakening properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci Lett 1995;189:43-46
23. Parmentier R, Anaclet C, Guhennec C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007;73:1157-1171 (Pubitemid 46413178)
24. Dugovic C, Meert TF, Ashton D, Clincke GH. Effects of ritanserin and chlordiazepoxide on sleep-wakefulness alterations in rats following chronic cocaine treatment. Psychopharmacology (Berl) 1992;108:263-270
25. Vyazovskiy VV, Achermann P, Tobler I. Sleep homeostasis in the rat in the light and dark period. Brain Res Bull 2007;74:37-44. (Pubitemid 47187911)
26. Simon P, Hemet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995;5:509-514
27. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994;17:436-437 (Pubitemid 24271517)
28. Leviel V. The reverse transport of DA, what physiological significance? Neurochem Int 2001;38:83-106.
29. Gray EG, Whittaker VP. The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. J Anat 1962;96:79-88.
30. Janowsky A, Neve K, Eshleman AJ, eds. Current protocols in neuroscience. Somerset, NJ: John Wiley & Sons, Inc., 1998:7.9.1-7.9.22.
31. Molina-Hernandez A, Nunez A, Sierra JJ, Arias-Montano JA. Histamine H3 receptor activation inhibits glutamate release from rat striatal synaptosomes. Neuropharmacology 2001;41:928-934 (Pubitemid 34024988)
32. Opp MR, Krueger JM. Anti-interleukin-1 beta reduces sleep and sleep rebound after sleep deprivation in rats. Am J Physiol 1994;266:R688-95.
33. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628
34. Le S, Gruner JA, Mathiasen JR, Marino MJ, Schaffhauser H. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 2008;325:902-909 (Pubitemid 351724342)
35. Baumann MH, Ayestas MA, Sharpe LG, Lewis DB, Rice KC, Rothman RB. Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. J Pharmacol Exp Ther 2002;301:1190-1197
36. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
37. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003;479:23-40.
38. Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 2007;52:405-414
39. Wisor JP, Dement WC, Aimone L, Williams M, Bozyczko-Coyne D. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006;85:492-499 (Pubitemid 46097059)
40. Loland CJ, Desai RI, Zou MF, et al. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 2008;73:813-823
41. Katz JL, Griffiths JW, Sharpe LG, De Souza EB, Witkin JM. Cocaine tolerance and cross-tolerance. J Pharmacol Exp Ther 1993;264:183-192
42. Kula NS, Baldessarini RJ, Tarazi FI, et al. [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol 1999;385:291-294
43. Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005;132:1027-1034
44. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992;591:319-326
45. Hunsley MS, Palmiter RD. Altered sleep latency and arousal regulation in mice lacking norepinephrine. Pharmacol Biochem Behav 2004;78:765-773
46. Gonzalez MM, Valatx JL, Debilly G. Role of the locus coeruleus in the sleep rebound following two different sleep deprivation methods in the rat. Brain Res 1996;740:215-226 (Pubitemid 26411302)
47. Zhang Y, Loonam TM, Noailles PA, Angulo JA. Comparison of cocaine-and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann N Y Acad Sci 2001;937:93-120. (Pubitemid 32613881)
48. Lee TH, Balu R, Davidson C, Ellinwood EH. Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors. Synapse 2001;41:301-310 (Pubitemid 32702251)
49. Venton BJ, Seipel AT, Phillips PE, et al. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci 2006;26:3206-3209
50. Roseboom PH, Gnegy ME. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site. Mol Pharmacol 1989;35:139-147
51. Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 2001;21:5916-5924 (Pubitemid 32737724)
52. Rothman RB. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 1990;46:L17-21.
53. Gerasimov MR, Franceschi M, Volkow ND, et al. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000;295:51-57 (Pubitemid 30746062)
54. Lile JA, Nader MA. The abuse liability and therapeutic potential of drugs evaluated for cocaine addition as predicted by animal model. Curr Neuropharmacol 2003;1:21-46.
55. Lile JA. Pharmacological determinants of the reinforcing effects of psychostimulants: relation to agonist substitution treatment. Exp Clin Psychopharmacol 2006;14:20-33.
56. Nelson RA, Boyd SJ, Ziegelstein RC, et al. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 2006;82:19-24. (Pubitemid 43289100)
57. Volkow ND, Wang GJ, Fowler JS, et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry 2005;57:640-646
58. Sidhpura N, Redfern P, Rowley H, Heal D, Wonnacott S. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem Pharmacol 2007;74:1292-1298 (Pubitemid 47417922)
59. Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007;568:112-123
60. Vaugeois JM, Bonnet JJ, Duterte-Boucher D, Costentin J. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 1993;230:195-201.
61. Izenwasser S, Terry P, Heller B, Witkin JM, Katz JL. Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors. Eur J Pharmacol 1994;263:277-283 (Pubitemid 24301306)
62. Hurd YL, Ungerstedt U. Ca2+ dependence of the amphetamine, nomifensine, and Lu 19-005 effect on in vivo dopamine transmission. Eur J Pharmacol 1989;166:261-269 (Pubitemid 19186763)
63. Hurd YL, Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 1989;166:251-260
64. Bueters TJ, Hoogstraate J, Visser SA. Correct assessment of new compounds using in vivo screening models can reduce false positives. Drug Discov Today 2009;14:89-94.
65. Green CE, LeValley SE, Tyson CA. Comparison of amphetamine metabolism using isolated hepatocytes from five species including human. J Pharmacol Exp Ther 1986;237:931-936
66. Kuhn CM, Schanberg SM, Breese GR. Metabolism of amphetamine by rat brain tissue. Biochem Pharmacol 1978;27:343-351 (Pubitemid 8249349)
67. Sulzer D, Galli A. Dopamine transport currents are promoted from curiosity to physiology. Trends Neurosci 2003;26:173-176 (Pubitemid 36411996)
68. Raiteri M, Cerrito F, Cervoni AM, Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 1979;208:195-202. (Pubitemid 9191708)
69. Heikkila RE, Orlansky H, Mytilineou C, Cohen G. Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 1975;194:47-56.